Adjuvant system AS01 is used in two candidate vaccines that have recently demonstrated efficacy in phase III trials: the malaria vaccine, RTS,S and the herpes zoster vaccine, HZ/su. AS01 is also in efficient in other candidate vaccines targeted against tuberculosis and human immunodeficiency virus...
Together with the TLR4-ligand MPL, QS-21 is part of the Adjuvant System AS01, a key component of the malaria and zoster candidate vaccines that display demonstrated clinical efficacy. However, the mechanism of action of QS-21 in this liposomal formulation is poorly understood. Upon intra-...
Adjuvant system AS01: helping to overcome the challenges of modern vaccines Expert Rev Vaccines, 16 (2017), pp. 55-63, 10.1080/14760584.2016.1213632 View in ScopusGoogle Scholar [19] A. Di Pasquale, P. Bonanni, N. Garcon, L.R. Stanberry, M. El-Hodhod, F. Tavares Da Silva Vaccine sa...
RF-induced local inflammation, such as cytokine/chemokine release and immune cell recruitment, was explored and compared with that induced by widely used chemical adjuvants, such as Alum, MPL, and AddaVax. As shown in Fig.1a, RF induced relatively low levels of cytokine gene expression exceptI...
Creative Commons.20 Safety of RTS,S from Phase I and Phase I/II Clinical Trial Studies All phase I and Phase I/II clinical trials aimed to study the safety of RTS,S were conducted on AS02 (formerly called SBAS2) adjuvant system. A total of 7 phase I and phase I/II studies were ...
such as alum, MF59, AS03, and AS01. We extensively discuss their composition, characteristics, mechanism of action, and effects on the immune system. Additionally, we summarize recent trends in adjuvant discovery, providing a brief overview of saponins, TLRs agonists, polysaccharides, nanoparticles,...
AS02, another Adjuvant System, is being evaluated in various contexts, where a strong T-cell response is needed to afford protection. Likewise, AS01 has been developed for vaccines where the induction of a yet stronger T-cell-mediated immune response is required. Altogether, the promising ...
MPLA is either adsorbed to aluminum phosphate in the adjuvant system 04 (AS04) used, e.g., in the hepatitis B vaccine Fendrix® [60] or formulated within the liposomal formulation AS01 which is, e.g., used in the malaria vaccine Mosquirix® [61]. However, in AIT, MPLA is currentl...
Recently, engineered nanoparticles (NPs) have been introduced as novel alternatives to traditional vaccine adjuvant. Metallic nanoparticles (MeNPs) are among the most promising NPs used for vaccine adjuvant as well as the delivery system that can improve immune responses against pathogens. Iron NPs, ...
Apart from aluminium salts, the only other licensed adjuvants in human vaccines are oil-in-water emulsions containing squalene (MF59, AS03), in vitro-assembled influenza-virus-like particles (virosomes), and, most recently, the liposome-based Adjuvant System AS01 (ref....